Please ensure Javascript is enabled for purposes of website accessibility

Why DaVita Inc. Sank Lower Today

By Brian Orelli, PhD - Oct 9, 2017 at 3:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst downgrade sent shares of the dialysis company heading south.

What happened

Warren Buffett might like it, but DaVita (DVA 0.07%) was down 9.7% at 3:42 p.m. EDT, after an analyst at J.P. Morgan downgraded the kidney-dialysis company from neutral to underweight, citing legal battles as a reason to be skeptical of DaVita's prospects.

So what

Earlier this year, DaVita and fellow dialysis company Fresenius Medical Care (FMS -1.25%) received subpoenas from the U.S. Department of Justice over their contributions to the American Kidney Fund, a charity that provides financial assistance for patients who need dialysis.

Highway sign that reads "Downgrade next exit"

Image source: Getty Images.

The relationships between the companies and the nonprofit have raised concerns: Would the donations from the two largest kidney-dialysis companies lead American Kidney Fund to favor patients going to those dialysis facilities, while shunning patients going to facilities that haven't made contributions? The charity has an agreement with the government that forbids it from choosing patients based on their clinics.

American Kidney Fund was also helping patients pay for private insurance rather than rely on Medicaid, which would pay the dialysis facilities less per patient than private insurers. Those insurers are trying to figure out which patients American Kidney Fund is subsidizing and remove them from their rolls.

Now what

DaVita hasn't disclosed the total number of commercial patients that American Kidney Fund is subsidizing, but the J.P. Morgan analyst estimates that 60% to 80% of DaVita's earnings power is derived from its relationship with the American Kidney Fund. That isn't actually 60% to 80% of DaVita's total patient population, but since those patients are more profitable, they represent a larger portion of earnings.

If the analyst is right on his estimate and the profitable patients go away through either a settlement or court order, it could be painful to DaVita's earnings.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of DaVita. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DaVita Inc. Stock Quote
DaVita Inc.
$89.64 (0.07%) $0.06
Fresenius Medical Care AG & Co. KGaA Stock Quote
Fresenius Medical Care AG & Co. KGaA
$18.16 (-1.25%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.